Literature DB >> 434035

Meperidine and normeperidine levels following meperidine administration during labor. II. Fetus and neonate.

B R Kuhnert, P M Kuhnert, A S Tu, D C Lin.   

Abstract

The time interval between the administration of meperidine to laboring patients and delivery may affect neonatal status, but sophisticated analytic techniques have not been used to determine the exposure of the fetus to meperidine at various drug-delivery intervals. By means of gas chromatography and mass spectrometry, the concentrations of meperidine and normeperidine (the principle metabolite of meperidine) were quantitated in the umbilical cord venous and arterial plasma at delivery and in the urine of the neonate for three days postpartum. Following 50 mg. of meperidine administered intravenously during labor, fetal exposure to meperidine was highest two to three hours after maternal medication while fetal exposure to normeperidine was highest four hours or more after medication. We conclude from this study that there is a definite but nonlinear relationship between the drug-delivery interval and the amount of meperidine and normeperidine an infant receives; and that the drug-delivery intervals resulting in maximum fetal exposure reported here correspond with those resulting in maximum neonatal depression reported by others.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 434035     DOI: 10.1016/0002-9378(79)90311-9

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  11 in total

Review 1.  Clinical pharmacokinetics of pethidine: 1982.

Authors:  D J Edwards; C K Svensson; J P Visco; D Lalka
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

Review 2.  Drug kinetics in childbirth.

Authors:  R L Nation
Journal:  Clin Pharmacokinet       Date:  1980 Jul-Aug       Impact factor: 6.447

3.  Placental transfer of pethidine and norpethidine and their pharmacokinetics in the newborn.

Authors:  P L Morselli; V Rovei
Journal:  Eur J Clin Pharmacol       Date:  1980-07       Impact factor: 2.953

4.  Maternal and fetal effects of intravenous patient-controlled fentanyl analgesia during labour in a thrombocytopenic parturient.

Authors:  O P Rosaeg; J B Kitts; G Koren; L J Byford
Journal:  Can J Anaesth       Date:  1992-03       Impact factor: 5.063

Review 5.  Clinical pharmacokinetics and pharmacodynamics of opioid analgesics in infants and children.

Authors:  K T Olkkola; K Hamunen; E L Maunuksela
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

Review 6.  Placental transfer of drugs administered to the mother.

Authors:  G M Pacifici; R Nottoli
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

Review 7.  Obstetric analgesia. Clinical pharmacokinetic considerations.

Authors:  J Kanto
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

Review 8.  Risk-benefit assessment of anaesthetic agents in the puerperium.

Authors:  J Kanto
Journal:  Drug Saf       Date:  1991 Jul-Aug       Impact factor: 5.606

9.  Maternal kinetics and transplacental passage of pethidine during labour.

Authors:  G Tomson; R I Garle; B Thalme; H Nisell; L Nylund; A Rane
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

10.  Prenatal and neonatal drug metabolism in man.

Authors:  A Rane; G Tomson
Journal:  Eur J Clin Pharmacol       Date:  1980-07       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.